The human leukocyte antigen HLA-B27 is strongly associated with spondyloarthropathies (SpA), a group of inflammatory rheumatic diseases including ankylosing spondylitis (AS). HLA-B27 is found in 90–95% of AS patients. It is also found in a lower proportion of patients with reactive arthritis and some forms of psoriatic arthritis (PsA). Twenty-four HLA-B27 subtypes have been detected and differ only by a small number of nucleotide substitutions within exons 2 and 3 of the HLA-B27 gene. Although the exact mechanism determining disease susceptibility is still unknown, testing for HLA-B27 is a valuable tool for the diagnosis of AS and SpA. Serological techniques such as the micro lymphocytotoxicity test (MLCT), flow cytometry (FC) and enzyme immunoassays (EIA) are typically used for the routine typing of HLA-B27. However, these techniques require fresh blood samples (viable cells) because they are based on the detection of cell surface structures by antibodies and are thus sensitive to downregulation or conformational changes of the HLA-B27 glycoprotein. Moreover, serological methods lack specificity especially in the presence of antigens that cross-react with HLA-B27, such as HLA-B7. Therefore, several molecular methods that do not require viable cells and are more accurate have been developed for HLA-B27 genotyping.
Intended Use
The NamuPlex™ HLA-B*27 Real-time PCR Kit is an in vitro diagnostic test using real-time PCR for the qualitative detection of nucleic acid to dertermine the presence or absence of the B*27 gene, a HLA-B allele, in blood (EDTA) from humans which provides information on ankylosing spondylitis disease.
NamuPlex™
HLA-B*27 Real-time PCR Kit
Cat. GNT-2001-1
Korea MFDS
Intended Use
Targets
Workflow
Results